GCC2 promotes non-small cell lung cancer growth by maintaining Golgi apparatus integrity and stimulating EGFR signaling pathways
Authors:
Preprint
- 12 March 2024
- preprint
- Published by Springer Nature in Research Square
Abstract
Fundamental changes in intracellular processes, such as overactive growth signaling pathways, are common in carcinomas and are targets of many cancer therapeutics. GRIP and coiled-coil containing 2 (GCC2) is a trans-Golgi network (TGN) golgin maintaining Golgi apparatus structure and regulating vesicle transport. Here, we found an aberrant overexpression of GCC2 in non-small cell lung cancer (NSCLC) and conducted shRNA-mediated gene knockdown to investigate the role of GCC2 in NSCLC progression. shRNA-mediated GCC2 knockdown suppressed NSCLC cell growth, migration, stemness, and epithelial-mesenchymal transition (EMT) in vitro and tumor growth in vivo. In addition, GCC2 knockdown suppressed cancer cell exosome secretion and the oncogenic capacity of cancer cell-derived exosomes. Mechanistically, GCC2 inhibition decreased epidermal growth factor receptor (EGFR) expression and downstream growth and proliferation signaling. Furthermore, GCC2 inhibition compromised Golgi structural integrity in cancer cells, indicating a functional role of GCC2 in regulating intracellular trafficking and signaling to promote lung cancer progression. Together, these findings suggest GCC2 as a potential therapeutic target for the treatment of NSCLC.Keywords
All Related Versions
- Version 1, 2024-03-12, Research Square
- Published version: Scientific Reports, 14 (1), 1.
This publication has 50 references indexed in Scilit:
- The clathrin adaptor complex-1 and Rab12 regulate post-golgi trafficking of WT epidermal growth factor receptor (EGFR)Journal of Biological Chemistry, 2023
- EGFR: An essential receptor tyrosine kinase-regulator of cancer stem cells2020
- Form and function of the Golgi apparatus: scaffolds, cytoskeleton and signallingFEBS Letters, 2019
- GCC2-ALK as a targetable fusion in lung adenocarcinoma and its enduring clinical responses to ALK inhibitorsLung Cancer, 2018
- Emerging functions of the EGFR in cancerMolecular Oncology, 2017
- Current knowledge on exosome biogenesis and releaseCellular and Molecular Life Sciences, 2017
- GOLM1 Modulates EGFR/RTK Cell-Surface Recycling to Drive Hepatocellular Carcinoma MetastasisCancer Cell, 2016
- DNA Damage Triggers Golgi Dispersal via DNA-PK and GOLPH3Cell, 2014
- ERK implication in cell cycle regulationBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2007
- Cyclin D1 in non-small cell lung cancer: A key driver of malignant transformationLung Cancer, 2007